Andreas Kuemmel1, Petra Simon2, Andrea Breitkreuz2, Julia Röhlig3, Ulrich Luxemburger2, Amelie Elsäßer4, Lars Henning Schmidt5, Martin Sebastian6, Ugur Sahin2, Özlem Türeci7, Roland Buhl3. 1. Department of Hematology, Medical Oncology & Pneumology, University Medical Center Mainz, 55131 Mainz, Germany. Electronic address: andreas.kuemmel@unimedizin-mainz.de. 2. Department of Hematology, Medical Oncology & Pneumology, University Medical Center Mainz, 55131 Mainz, Germany; TRON gGmbH, Translational Oncology at the University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany. 3. Department of Hematology, Medical Oncology & Pneumology, University Medical Center Mainz, 55131 Mainz, Germany. 4. Institute of Medical Biostatistics, Epidemiology and Informatics, Johannes Gutenberg-University, 55101 Mainz, Germany. 5. Department of Medicine A, University Medical Center Muenster, 48149 Muenster, Germany. 6. Department of Medicine III, Goethe-University Frankfurt, 60590 Frankfurt am Main, Germany. 7. Ganymed Pharmaceuticals AG, Freiligrathstr.12, 55131 Mainz, Germany.
Abstract
OBJECTIVE: The cancer/testis (C/T) antigen Transmembrane Phosphatase with TEnsin homology (TPTE) is aberrantly expressed in many tumors including lung cancer. In the present study, we analyzed TPTE-auto-antibodies in lung cancer patients. METHODS: Using a crude-lysate ELISA, we analyzed a large cohort of 307 sera from lung cancer patients and 47 healthy donors for TPTE-specific autoantibodies. Sero-reactivity was correlated with clinical parameters and patients' survival. RESULTS: TPTE-specific antibodies were detected in 41 of 307 (13.4%) sera from lung cancer patients. Based on an optimal cut-off value calculated by ROC curve analysis sensitivity for diagnosing lung cancer was 52% and specificity was 72%. TPTE sero-positivity was not associated with tumor stage, tumor histology, gender or age. Multivariate analysis indicated that TPTE sero-positivity is associated with prolonged survival in patients with lung cancer, but established prognostic factors for survival prediction such as stage and histology remain indispensable. CONCLUSION: Autoantibodies against TPTE occur spontaneously in lung cancer patients. TPTE sero-reactivity has moderate sensitivity and specificity for diagnosing lung cancer and is a positive prognostic marker.
OBJECTIVE: The cancer/testis (C/T) antigen Transmembrane Phosphatase with TEnsin homology (TPTE) is aberrantly expressed in many tumors including lung cancer. In the present study, we analyzed TPTE-auto-antibodies in lung cancerpatients. METHODS: Using a crude-lysate ELISA, we analyzed a large cohort of 307 sera from lung cancerpatients and 47 healthy donors for TPTE-specific autoantibodies. Sero-reactivity was correlated with clinical parameters and patients' survival. RESULTS:TPTE-specific antibodies were detected in 41 of 307 (13.4%) sera from lung cancerpatients. Based on an optimal cut-off value calculated by ROC curve analysis sensitivity for diagnosing lung cancer was 52% and specificity was 72%. TPTEsero-positivity was not associated with tumor stage, tumor histology, gender or age. Multivariate analysis indicated that TPTEsero-positivity is associated with prolonged survival in patients with lung cancer, but established prognostic factors for survival prediction such as stage and histology remain indispensable. CONCLUSION: Autoantibodies against TPTE occur spontaneously in lung cancerpatients. TPTEsero-reactivity has moderate sensitivity and specificity for diagnosing lung cancer and is a positive prognostic marker.
Authors: Yasemin Ceyhan; Manqi Zhang; Carlos G Sandoval; Alexander I Agoulnik; Irina U Agoulnik Journal: Biol Reprod Date: 2022-10-11 Impact factor: 4.161
Authors: Andreas Kuemmel; Astrid Alflen; Lars Henning Schmidt; Martin Sebastian; Rainer Wiewrodt; Arik Bernard Schulze; Roland Buhl; Markus Radsak Journal: Sci Rep Date: 2018-07-17 Impact factor: 4.379